Published in AIDS on November 04, 2005
Viral quasispecies evolution. Microbiol Mol Biol Rev (2012) 2.69
Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res (2008) 2.40
Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology (2009) 1.99
Host hindrance to HIV-1 replication in monocytes and macrophages. Retrovirology (2010) 1.33
Circulating monocytes in HIV-1-infected viremic subjects exhibit an antiapoptosis gene signature and virus- and host-mediated apoptosis resistance. J Immunol (2009) 1.20
Low-level plasma HIVs in patients on prolonged suppressive highly active antiretroviral therapy are produced mostly by cells other than CD4 T-cells. J Med Virol (2009) 1.19
Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology (2013) 1.18
Restriction of HIV-1 genotypes in breast milk does not account for the population transmission genetic bottleneck that occurs following transmission. PLoS One (2010) 1.13
Cross-clade ultrasensitive PCR-based assays to measure HIV persistence in large-cohort studies. J Virol (2014) 1.12
Amount of HIV DNA in peripheral blood mononuclear cells is proportional to the severity of HIV-1-associated neurocognitive disorders. J Neuropsychiatry Clin Neurosci (2009) 1.08
HIV DNA and dementia in treatment-naïve HIV-1-infected individuals in Bangkok, Thailand. Int J Med Sci (2006) 1.04
Regional cortical thinning associated with detectable levels of HIV DNA. Cereb Cortex (2011) 1.02
Circulating monocytes are not a major reservoir of HIV-1 in elite suppressors. J Virol (2011) 0.99
The evolution of HIV: inferences using phylogenetics. Mol Phylogenet Evol (2011) 0.94
Lack of in vivo compartmentalization among HIV-1 infected naïve and memory CD4+ T cell subsets. Virology (2009) 0.90
HIV persistence in the setting of antiretroviral therapy: when, where and how does HIV hide? J Virus Erad (2015) 0.87
Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND. J Neuroimmune Pharmacol (2013) 0.87
A phylogenetic and Markov model approach for the reconstruction of mutational pathways of drug resistance. Bioinformatics (2009) 0.82
Analysis of multiple cell reservoirs expressing unspliced HIV-1 gag-pol mRNA in patients on antiretroviral therapy. Future Virol (2012) 0.82
Establishment and Reversal of HIV-1 Latency in Naive and Central Memory CD4+ T Cells In Vitro. J Virol (2016) 0.80
Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success. Can J Gastroenterol (2010) 0.80
Inferring within-patient HIV-1 evolutionary dynamics under anti-HIV therapy using serial virus samples with vSPA. BMC Bioinformatics (2009) 0.79
Successful isolation of infectious and high titer human monocyte-derived HIV-1 from two subjects with discontinued therapy. PLoS One (2013) 0.79
Varied sensitivity to therapy of HIV-1 strains in CD4+ lymphocyte sub-populations upon ART initiation. AIDS Res Ther (2010) 0.79
Identification and characterization of HIV-1 latent viral reservoirs in peripheral blood. J Clin Microbiol (2014) 0.77
Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT). Eur J Med Res (2009) 0.77
Foamy virus vectors for HIV gene therapy. Viruses (2013) 0.77
HIV migration between blood plasma and cellular subsets before and after HIV therapy. J Med Virol (2015) 0.75
Lack of concordance between residual viremia and viral variants driving de novo infection of CD4(+) T cells on ART. Retrovirology (2016) 0.75
Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet (2006) 10.91
Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med (2008) 6.60
Ribavirin for chronic hepatitis E virus infection in transplant recipients. N Engl J Med (2014) 4.70
Hepatitis E. Lancet (2012) 4.43
Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence. PLoS Pathog (2008) 3.02
Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis (2011) 2.75
A systematic review of computer-based patient record systems and quality of care: more randomized clinical trials or a broader approach? Int J Qual Health Care (2004) 2.31
Hepatitis E virus infection. Clin Microbiol Rev (2014) 2.21
Diversity of beta-lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae. Antimicrob Agents Chemother (2002) 2.11
Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. AIDS (2008) 2.04
Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants. Gastroenterology (2011) 2.01
Hepatitis E virus genotype 3 diversity, France. Emerg Infect Dis (2009) 1.99
Hepatitis E in the south west of France in individuals who have never visited an endemic area. J Med Virol (2004) 1.85
High prevalence of anti-hepatitis E virus antibodies in blood donors from South West France. J Med Virol (2008) 1.84
Correlates of late HIV diagnosis: implications for testing policy. Int J STD AIDS (2007) 1.78
Characteristics of autochthonous hepatitis E virus infection in solid-organ transplant recipients in France. J Infect Dis (2010) 1.75
Hepatitis E virus and neurologic disorders. Emerg Infect Dis (2011) 1.70
French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002. J Acquir Immune Defic Syndr (2005) 1.63
Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother (2010) 1.53
An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients. Transplantation (2015) 1.52
Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol (2007) 1.49
Does chronic hepatitis E virus infection exist in immunocompetent patients? Hepatology (2014) 1.49
Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J Clin Invest (2011) 1.49
Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. Nephrol Dial Transplant (2010) 1.48
Hepatitis E is an autochthonous disease in industrialized countries. Analysis of 23 patients in South-West France over a 13-month period and comparison with hepatitis A. Gastroenterol Clin Biol (2006) 1.47
Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS (2009) 1.46
Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study. J Clin Microbiol (2005) 1.45
Ribavirin therapy inhibits viral replication on patients with chronic hepatitis e virus infection. Gastroenterology (2010) 1.44
Influence of immunosuppressive therapy on the natural history of genotype 3 hepatitis-E virus infection after organ transplantation. Transplantation (2010) 1.44
HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One (2009) 1.42
Occult hepatitis C virus infection in hemodialysis patients: examining the evidence. Am J Kidney Dis (2009) 1.39
Population-based sequencing of the V3 region of env for predicting the coreceptor usage of human immunodeficiency virus type 1 quasispecies. J Clin Microbiol (2007) 1.39
R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2005) 1.37
Long-term impact of renal transplantation on liver fibrosis during hepatitis C virus infection. Gastroenterology (2002) 1.36
Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study. J Acquir Immune Defic Syndr (2007) 1.35
New natural intergenotypic (2/5) recombinant of hepatitis C virus. J Virol (2007) 1.34
High-Risk groups for late diagnosis of HIV infection: a need for rethinking testing policy in the general population. AIDS Patient Care STDS (2006) 1.34
CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. AIDS (2010) 1.32
Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother (2005) 1.30
Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism. J Clin Microbiol (2009) 1.30
FOXP3 mRNA levels are decreased in peripheral blood CD4+ lymphocytes from HIV-positive patients. J Acquir Immune Defic Syndr (2005) 1.27
Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. Liver Transpl (2010) 1.26
Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. J Clin Virol (2009) 1.24
Stable prevalence of genotypic drug resistance mutations but increase in non-B virus among patients with primary HIV-1 infection in France. AIDS (2003) 1.24
Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses. J Acquir Immune Defic Syndr (2010) 1.24
Factors of intermittent HIV-1 excretion in semen and efficiency of sperm processing in obtaining spermatozoa without HIV-1 genomes. AIDS (2004) 1.22
Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. J Med Virol (2006) 1.22
Evolution of human immunodeficiency virus type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. J Infect Dis (2002) 1.20
The hepatitis C virus epidemic in Cameroon: genetic evidence for rapid transmission between 1920 and 1960. Infect Genet Evol (2006) 1.19
TaqMan amplification system with an internal positive control for HCV RNA quantitation. J Clin Virol (2004) 1.19
Hepatitis C virus infection in cameroon: A cohort-effect. J Med Virol (2005) 1.18
Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol (2010) 1.17
Genotypic prediction of HIV-1 subtype D tropism. Retrovirology (2011) 1.16